Stem cell specialist Miracell Co., Ltd. to invest KRW 3 billion to build a production facility in the Hwasun Vaccine Industrial Complex.
-The only bio company to participate in DUPEX
– 2022 IPO with technology-specific listing on the horizon
Stem cell specialist Miracell Co., Ltd. (CEO Shin Hyun-soon) announced on November 4th at a signing ceremony at the 2021 Hwasun International Vaccine Forum that it would invest approximately 3 billion won in the construction of a production plant in the Hwasun Vaccine Industrial Complex, a state-of-the-art medical complex. As a leading company in stem cell therapy and medical devices,
this agreement will actively contribute to fostering local talent and expanding employment.
Miracell Co., Ltd., which began its medical business in 1986, was launched as a stem cell specialist in 2009.
Leveraging its decades of expertise, Miracell is pioneering the popularization of the domestic stem cell market with its next-generation bio-regenerative medical device, the “Smart M-cell 2.”
“Smart Mcell 2” is a cutting-edge cell extraction system capable of selectively isolating and extracting large quantities of stem cells, which exist in small quantities and are difficult to isolate. If cells collide or become activated during separation, they will be considered dead even when injected into the body. Therefore, the most crucial technology is to extract live, fresh cells. “Smart Mcell 2” met these stringent requirements, receiving NET New Health Technology certification from the Ministry of Health and Welfare and approval from the Ministry of Food and Drug Safety in February 2021.
At Seoul National University Bundang Hospital, a performance comparison test of the Smart Mcell 2, a bone marrow and blood stem cell extraction device with a centrifuge capable of selective separation, and the world’s leading product, SmartPrep, showed comparable or superior performance. Miracell’s bio-regenerative medical devices are currently being used across various medical specialties at major hospitals in Korea.
Miracell attracted the attention of military officials as the only bio company to participate in the “2021 DUPEX KOREA Asia Defense Exhibition,” held on October 19th.”DUPEX KOREA” is an international event with a 25-year history, attended by high-ranking military and security officials, including Ministers of Defense, Chiefs of Staff, and the Director of the Defense Acquisition Program Administration (DAPA) from over 70 countries.
“Smart Mcell 2,” which was selected as an innovative product by the Public Procurement Service, is expected to accelerate the recovery of soldiers from trauma and chronic pain that may occur during training through stem cell therapy,
and was highly praised for its potential to contribute to national defense through regenerative medicine.
Following its participation in KIMES Seoul, Korea’s largest medical device exhibition, Miracell also participated in KIMES Busan in October, signing contracts with numerous hospitals and clinics, expanding its market share to small cities in the Yeongnam region.
Miracell shares stem cell medical technology through a network of hospitals and clinics affiliated with the Cellpia Global Platform (CGP).
Over 60 CGP hospitals and clinics are located in Gangnam, Seoul, and other major cities across the country, covering a variety of specialties, including orthopedics, plastic surgery, dermatology, and family medicine. Miracell provides comprehensive services, including education, technology transfer, medical equipment setup, and marketing, to ensure safer stem cell treatments.
Ahead of its IPO in 2022, Miracell is actively pursuing its growth and positioning itself as a leader in the bio industry.